WallStreetZenWallStreetZen

NASDAQ: ARCT
Arcturus Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ARCT

Based on 3 analysts offering 12 month price targets for Arcturus Therapeutics Holdings Inc.
Min Forecast
$51.00+114.38%
Avg Forecast
$58.67+146.6%
Max Forecast
$71.00+198.44%

Should I buy or sell ARCT stock?

Based on 3 analysts offering ratings for Arcturus Therapeutics Holdings Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARCT stock forecasts and price targets.

ARCT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-28
lockedlocked$00.00+00.00%2023-08-22
lockedlocked$00.00+00.00%2023-07-24

1 of 1

Forecast return on equity

Is ARCT forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is ARCT forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

ARCT revenue forecast

What is ARCT's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$200.1M-32.45%
Avg 2 year Forecast
$286.4M-3.31%
Avg 3 year Forecast
$752.8M+154.12%
ARCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARCT earnings growth forecast

How is ARCT forecast to perform vs Biotechnology companies and vs the US market?
Company
67.63%
Industry
8.17%
Market
17.9%
ARCT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ARCT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ARCT's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ARCT revenue growth forecast

How is ARCT forecast to perform vs Biotechnology companies and vs the US market?
Company
32.52%
Industry
34.65%
Market
7.68%
ARCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARCT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARCT$23.79$58.67+146.60%Strong Buy
FDMT$14.94$33.00+120.88%Strong Buy
RVNC$7.37$24.75+235.82%Strong Buy
CNTA$6.65$10.00+50.38%Buy
TVTX$8.64$18.00+108.33%Strong Buy
View Top Biotech Stocks

Arcturus Therapeutics Holdings Stock Forecast FAQ

Is Arcturus Therapeutics Holdings Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ARCT) stock is to Strong Buy ARCT stock.

Out of 3 analysts, 1 (33.33%) are recommending ARCT as a Strong Buy, 2 (66.67%) are recommending ARCT as a Buy, 0 (0%) are recommending ARCT as a Hold, 0 (0%) are recommending ARCT as a Sell, and 0 (0%) are recommending ARCT as a Strong Sell.

If you're new to stock investing, here's how to buy Arcturus Therapeutics Holdings stock.

What is ARCT's revenue growth forecast for 2023-2025?

(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 32.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Arcturus Therapeutics Holdings's revenue in 2023 is $296,237,000.On average, 3 Wall Street analysts forecast ARCT's revenue for 2023 to be $5,347,338,733, with the lowest ARCT revenue forecast at $4,035,223,132, and the highest ARCT revenue forecast at $7,578,202,489. On average, 3 Wall Street analysts forecast ARCT's revenue for 2024 to be $7,654,363,985, with the lowest ARCT revenue forecast at $3,493,541,192, and the highest ARCT revenue forecast at $11,392,156,432.

In 2025, ARCT is forecast to generate $20,116,950,203 in revenue, with the lowest revenue forecast at $4,707,582,165 and the highest revenue forecast at $31,343,796,103.

What is ARCT's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ARCT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is ARCT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ARCT price target, the average ARCT price target is $58.67, with the highest ARCT stock price forecast at $71.00 and the lowest ARCT stock price forecast at $51.00.

On average, Wall Street analysts predict that Arcturus Therapeutics Holdings's share price could reach $58.67 by Nov 28, 2024. The average Arcturus Therapeutics Holdings stock price prediction forecasts a potential upside of 146.6% from the current ARCT share price of $23.79.

What is ARCT's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ARCT) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.